Cardium Therapeutics (NYSE:CXM) appealed to U.S. federal regulators for 510(k) clearance of its Excellagen wound care product after making several modifications and including more specific labeling.
Cardium Therapeutics
Cardium Therapeutics claims patent win over Boston Scientific
Bankers’ outlook grim for U.S. IPOs | Wall Street Beat
Bankers aren’t expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.
About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.
Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.
Zoll shares spike 23 percent on record 2011 sales and earnings | Earnings Roundup
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.